BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
Dec 9, 2024
VANCOUVER, BC / December 9, 2024 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT) (OTC MARKETS: BNXTF) (FSE: BXT), a bioscience company specializing...